Literature DB >> 3511819

Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.

V J Marder, R L Rothbard, P G Fitzpatrick, C W Francis.   

Abstract

The ability of anisoylated plasminogen: streptokinase activator complex (APSAC) to induce coronary artery reperfusion after bolus intravenous injection (2 to 4 minutes) was assessed in 29 patients with acute transmural myocardial infarction and complete coronary artery occlusion. A 5-mg dose resulted in reperfusion in 3 of 14 patients (21%); a 5-mg plus 10-mg regimen was successful in 3 of 7 (43%); and a 30-mg dose induced reperfusion in 9 of 15 (60%). Rethrombosis occurred in only 1 of 15 patients (7%) who received 30 mg, as determined by repeat angiography at 24 hours. The mean interval after injection until reperfusion was 35 minutes with the 30-mg dose, and bleeding occurred at the femoral artery catheterization site in only 3 of 15 patients (20%). Intracoronary streptokinase therapy achieved reperfusion in only 2 of the 6 patients in whom the 30-mg dose failed, indicating that this dose of APSAC was sufficient by itself in 9 of 11 (83%) successfully treated patients. Because therapy can be completed within 2 to 4 minutes, APSAC appears to be a most suitable fibrinolytic agent for early treatment of the coronary artery thrombosis associated with acute transmural myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511819     DOI: 10.7326/0003-4819-104-3-304

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

Review 1.  Use of plasminogen activators in venous thrombosis.

Authors:  J Hirsh; A G Turpie
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

2.  Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

Authors:  J P Monassier; M Hanssen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Modern treatment of pulmonary embolism.

Authors:  C M Kessler
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Acute coronary occlusion and reperfusion. Reliability of angiographic classification and grading.

Authors:  S G Sorensen; R A Hackworthy; P G Fitzpatrick; W H Barry; R L Menlove; J L Anderson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.

Authors:  V J Marder; R L Rothbard; P G Fitzpatrick; C W Francis; E C Norry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Reagents for reversible coupling of proteins to the active centres of trypsin-like serine proteinases.

Authors:  S B Kalindjian; R A Smith
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

7.  Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.

Authors:  J J Hoffmann; J J Bonnier; J B de Swart; P Custers; M Vijgen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  R A Hackworthy; S G Sorensen; R L Menlove; J L Anderson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 9.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

Review 10.  Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.

Authors:  J P Monk; R C Heel
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.